Gene testing aims to make cancer meds safer
NCT ID NCT05166694
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a Personalized Therapeutics Clinic (PTC) can lower the risk of harmful drug interactions in cancer patients. Participants get genetic testing to see how their medications interact with each other and with their genes. The goal is to help doctors prescribe more safely and reduce side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- genetic testing and personalized prescribing advice
- What this could lead to
- If it works, this could help doctors prescribe safer medication combinations for cancer patients, reducing side effects and improving treatment.
- What could go wrong
- This is an early-stage study focused on measuring interactions, not on curing disease. Results may not apply to all patients or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Chicago Medicine
RECRUITINGChicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Can your own immune cells beat advanced cancer?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare